Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference .
The presentation will take place as follows:
- Date: Tuesday, April 10th , 2018
- Time: 2:10 pm CEST
- Venue: Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
Pharnext’s first-in-class PLEODRUG™, PXT3003, is currently in an international Phase 3 trial for the treatment of the rare disease Charcot-Marie-Tooth disease type 1A. The results of this trial are expected before the end of 2018.
If you are interested in meeting the Pharnext management team during this event or if you need more information about Pharnext's participation, please send an email to firstname.lastname@example.org
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com .
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
Caroline Carmagnol / Aurore Gangloff
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Marion Janic, +1 212 223 4017
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-GUIDEWIRE-SOFTWARE19.2.2019 22:17:49 | Pressemeddelelse
Guidewire Software Announces Hexaware as New Consulting Alliance Partner
NY-IFF19.2.2019 22:17:08 | Pressemeddelelse
IFF Acquires The Additive Advantage; Expands Scent, Taste, and Actives Delivery Capabilities
WI-ROCKWELL-AUTOMATION19.2.2019 22:07:08 | Pressemeddelelse
Rockwell Automation and Schlumberger Enter Joint Venture Agreement to Create Sensia, the Oil and Gas Industry’s First Fully Integrated Automation Solutions Provider
IDEMIA19.2.2019 17:09:11 | Pressemeddelelse
IDEMIA Will Present Its 2018 Annual Financial Results to Investors on February 20, 2019
ICONECTIV19.2.2019 16:02:07 | Pressemeddelelse
Zain Group Drives Operational Efficiencies, Financial Compliance with iconectiv’s Comprehensive Fixed Asset Management Solution
CA-SONGTRADR19.2.2019 15:05:13 | Pressemeddelelse
Songtradr Acquires Leading Global Music Licensing Agency, Big Sync Music
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum